Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication—from IFN based era to IFN-free DAA era

Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication—from IFN based era to IFN-free DAA era

Toru Ishikawa

Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan

Correspondence to: Toru Ishikawa, MD, PhD. Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, 280-7 Teraji, Niigata 950-1104, Japan. Email: toruishi@ngt.saiseikai.or.jp.

Submitted Sep 27, 2019. Accepted for publication Oct 09, 2019.

doi: 10.21037/hbsn.2019.10.03

Chronic hepatitis C virus (HCV) infection is a public health issue which effects people throughout the world, with more than 71 million people effected, and 400,000 deaths annually (1). HCV, which is when active carriage of HCV RNA is in the blood, is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (2). Among HCV infected cirrhotic patients, the incidence rate of HCC steadily increases with increased degree of fibrosis, with annual reported incidence of 1.4% to 7% respectively (3). The eradication of the virus and therefore prevention of HCC development and liver related death is the ultimate treatment objective for chronic HCV. In 1991, the first treatment approved by the Food & Drug Administration (FDA) to treat chronic hepatitis C (CHC) was IFNα-2b monotherapy (4), which allowed 15–20% of sustained virological response (SVR) and also induced major side effects such as asthenia, neutropenia, myalgia and influenza-like syndromes (5). In 1998, SVR rates increased to 38% in IFNα-2b and daily oral administration of ribavirin (RBV) combination treated patients (6). In 2001 and 2002, the FDA approved pegylated-IFN (PEG-IFN)α-2b and PEG-IFNα-2a respectively, which allowed IFN-based treatment to be administered weekly. The combination of PEG-IFNα-2a or PEG-IFNα-2b and ribavirin allowed SVR in 56% and 54% of treated patients (7). This regimen given for 6 to 12 months depending on the HCV genotype became the new standard of care (4). After 10 years of stagnation with PEG-IFN/RBV combination, a desirable change spread over several stages. The first stage in 2011 was observed with the launch of the first direct-acting antiviral agents (DAAs). More than 75% of patients infected with HCV genotype 1 who were treated with NS3/4A protease inhibitors in combination with PEG-IFNα achieved SVR, however both had clinically significant side effects, increasing the daily pill burden (8). This treatment was approved since patients treated with IFN-based therapy achieving SVR have been shown to have a significantly lower risk of developing HCC than those who did not (9).

Therefore, treatment of HCV infection has been through a recent revolution since the advent of the latest second-generation, DAA agents of all oral IFN-free regimens based on anti-NS5A and NS5B polymerase inhibitors and 2nd generation protease inhibitors increased SVR rates to 90–98% in naïve and PEG-IFN/RBV-experienced patients from 2014 (10). DAAs allow a virological cure in almost all of the treated patients, but this high efficiency is still uncertain regarding the association with perfect elimination of HCC occurrence.

Nagaoki et al. found that the risk for developing HCC after viral eradication by IFN-free DAA therapy may be similar to that in IFN-based therapy (11).

Further, Calvaruso et al. also reported that HCV viral clearance with DAA treatment lowers the risk of HCC occurrence, even in those patients with more advanced cirrhosis (12). However, the risk of HCC development remains even after SVR, and therefore the need for long-term follow-up in cirrhotic patients is still high (13).

It is unclear if HCC risk declines over time after the eradication of HCV. Progressive fibrosis, assessed by sequential biopsies, was significantly correlated with development of HCC in patients achieving SVR for HCV.

After SVR was achieved, fibrosis regression was significantly associated with patient’s platelet count and age. The index calculated from age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count (PLT), Fibrosis score 4 (FIB-4), has been identified with high accuracy as a biochemical marker to predict hepatic fibrosis and cirrhosis (14).

In contrast to this, patients of advanced fibrosis or cirrhosis have the a very low risk of developing HCC in patients with no or only mild fibrosis who achieved SVR. Therefore, most HCV guidelines have almost no mention of HCC surveillance for this patient population.

As analyzed by Ioannou et al., HCC annual incidence over time following the eradication of HCV and identified dynamic markers of HCC risk, they concluded that patients of cirrhosis before an SVR to treatment for HCV infection continued to have high risk for HCC, even if the patient’s FIB-4 index score decreases, and should continue for surveillance (15).

Patients with FIB-4 scores ≥3.25 but without cirrhosis have a high enough risk to warrant HCC surveillance, especially if the patient’s FIB-4 remains ≥3.25 post-SVR (15).

This tells us that continued follow-up will be necessary in order to determine potential benefits related to the HCC development and mortality with and without cirrhosis, and Fib-4 score.

Further studies are required to assess patients in different geographical regions and ethnicity, in order to prove utility as a predictive tool.


Funding: None.


Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2019.10.03). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-ncnd/4.0/.


  1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76. [Crossref] [PubMed]
  2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5. [Crossref] [PubMed]
  3. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53. [Crossref] [PubMed]
  4. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: An epoch coming to an end. Nat Rev Immunol 2013;13:535-42. [Crossref] [PubMed]
  5. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-62. [Crossref] [PubMed]
  6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92. [Crossref] [PubMed]
  7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. [Crossref] [PubMed]
  8. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. [Crossref] [PubMed]
  9. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37. [Crossref] [PubMed]
  10. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [Crossref] [PubMed]
  11. Nagaoki Y, Imamura M, Aikata H, et al. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One 2017;12:e0182710. [Crossref] [PubMed]
  12. Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-21.e4. [Crossref] [PubMed]
  13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. [Crossref] [PubMed]
  14. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [Crossref] [PubMed]
  15. Ioannou GN, Beste LA, Green PK, et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019;157:1264-78. [Crossref] [PubMed]
Cite this article as: Ishikawa T. Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication—from IFN based era to IFN-free DAA era. Hepatobiliary Surg Nutr 2020;9(2):227-229. doi: 10.21037/hbsn.2019.10.03